Phase 3 study of 13-valent pneumococcal conjugate vaccine with meningococcal C vaccine in healthy Spanish infants

Phase 3, randomised, double-blind trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease and meningococcal disease (2 arms), sponsored by Wyeth. Primary endpoints: Meningococcal C immune response after toddler dose, Proportion achieving prespecified antibody levels for concomitant antigens and 3 more. Started Mar 2007; status: completed.